During the past decade, Dana Farber Cancer Institute/Pharmacy conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 1 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Dana Farber Cancer Institute/Pharmacy" are "Carcinoma, Non-Small-Cell Lung" (1 trials) and "Non Small Cell Lung Cancer ALK Positive or ROS1 Positive" (1 trials). Many other conditions were trialed in "Dana Farber Cancer Institute/Pharmacy" in a lesser frequency.

Most popular intervention types in "Dana Farber Cancer Institute/Pharmacy" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Lorlatinib" (1 trials) and "PF-02341066" (1 trials). Other intervention names were less common.

The vast majority of trials in "Dana Farber Cancer Institute/Pharmacy" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Dana Farber Cancer Institute/Pharmacy". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Dana Farber Cancer Institute/Pharmacy, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Dana Farber Cancer Institute/Pharmacy, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".